A Randomized, Single Blind, Multi-Center Phase II Study to Evaluate the Effect of Three Different Doses of Androxal and AndroGel on 24-Hour Luteinizing Hormone and Testosterone in Normal Healthy Men

Trial Profile

A Randomized, Single Blind, Multi-Center Phase II Study to Evaluate the Effect of Three Different Doses of Androxal and AndroGel on 24-Hour Luteinizing Hormone and Testosterone in Normal Healthy Men

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2015

At a glance

  • Drugs Enclomifene (Primary) ; Testosterone
  • Indications Hypogonadism
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 10 Apr 2013 Results reporting the effects of treatment on hormone levels, including levels of insulin-like growth factor-1, presented at the 104th Annual Meeting of the American Association for Cancer Research.
    • 28 Dec 2011 A final clinical trial report is expected to be submitted to the Divison of Reproductive and Urologic Products of the FDA in February 2012, according to a Repros Therapeutics media release.
    • 01 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top